CIRIUM
The major US carriers made a clean sweep of the top four places as aviation analytics firm Cirium revealed its World Airline Passenger Rankings for 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220831005886/en/
US majors take top spot while low-cost carriers rise up the Cirium global airlines rankings. (Graphic: Business Wire)
American Airlines stays on top of the ranking again in 2021, followed by Delta Air Lines, United Airlines and Southwest Airlines, demonstrating the strength of the recovery that continues to take place in the US domestic market.
Overall, airlines in North America showed 75% growth from the low point in 2020, although still ending last year down by 40% on 2019 traffic levels, as measured in Revenue Passenger Kilometers/Miles (RPKs/RPMs).
The ranking, which is based on over 600 operators tracked in the Cirium airline database, shows that world traffic ended 2021 down by 57% against the pre-pandemic peak. In terms of passenger numbers, the total stood at 2.3 billion for the year, representing around half of the volumes from the peak in 2019.
Low-cost carriers continued to rise up the rankings across the regions. Ryanair cemented its place as Europe’s largest carrier, sitting in fifth place just below Southwest, and was the only European airline to make it into the top 10.
Europe’s major network carriers have fared less well over the past couple of years, as demand for long-haul, premium travel remained depressed. Although Air France held steady at 13th place, Lufthansa slipped down the rankings and British Airways fell out of the top 20 altogether. Virgin Atlantic also dropped more than 50 places as it too suffered from the slow return of long-haul and premium traffic.
The big three carriers in mainland China – China Southern, China Eastern and Air China – held their place toward the top of the ranking, although that could change after a renewed round of COVID-19 lockdowns in Chinese cities so far this year.
Across Asia Pacific as a whole – in stark contrast to recovery in all other world regions – airlines saw traffic fall again last year. Cathay Pacific slipped spectacularly, falling out of the top 100 ranking entirely following Hong-Kong’s pursuit of an aggressive zero-COVID strategy. It was not alone. Carriers across the region in Indonesia, Malaysia, South Korea and Thailand also continued to shrink.
In Japan, All Nippon Airways and Japan Airlines had lost nearly 85% of their traffic in 2020 and were still down by around 75% by the end of 2021. Both fell steeply down the rankings as a result.
Jeremy Bowen, Cirium CEO, said: “Pre-pandemic, Asia Pacific airlines held the single largest share of global passenger traffic, with over a third of the world total. By 2021 the region was overtaken by North America, led by the strong recovery in domestic US flying.”
Two Gulf carriers, Emirates and Qatar Airways, both retained their position within the top 10 airlines, although the gap between them narrowed. Emirates slipped four places to sit just ahead of a rising Qatar Airways, which has made a point of maintaining as much of its network as possible.
Turkish Airlines, helped by an extensive domestic market free of cross-border travel restrictions, climbed four places to 10th in the latest ranking compared with 2019.
The Cirium ranking highlights the struggle which mainline carriers have faced, especially those relying on a strong mix of business travel and long-haul flying. By 2021 their share of world passenger traffic had slipped some five percentage points to 64%. That decline was largely picked up by low-cost carriers, who raised their share to 26%.
Cirium’s World Airline Passenger Ranking 2021 is a premium analysis available in Cirium Dashboard. The report features:
- The Top 200 airlines by passenger traffic
- The Top 50 airline groups by passenger traffic
- The Top 50 airlines by passenger volume
- Passenger traffic by region and by airline type 2019-2021
- Share of passenger traffic by airline region and airline type
- Share of passenger volume by airline type
Click here to download the full report.
Ends
About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.
For further information please follow Cirium updates on LinkedIn or Twitter or visit www.cirium.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220831005886/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
